28 January 2021
Latham & Watkins Advises Underwriters in CureVac’s US$450 Million Follow-on Public Offering of Common Shares
Advising firms
Deal team
5 lawyers named| Lawyer | Firm | Seniority | Practice | Office |
|---|---|---|---|---|
| Nathan Ajiashvili Lead | Latham & Watkins LLP | Partner | capital markets | New York |
| Alison Haggerty Lead | Latham & Watkins LLP | Partner | capital markets | New York |
| Adam Johnson | Latham & Watkins LLP | Associate | capital markets | Not stated |
| Patrick Maguire | Latham & Watkins LLP | Associate | capital markets | Not stated |
| MacLane Taggart | Latham & Watkins LLP | Associate | capital markets | Not stated |
2 more lawyers on this deal. Register free to see the full deal team, with seniority, practice and office.
REGISTER FREE SIGN INWant co-counsel patterns, repeat clients and alerts when these firms land their next deal? Get Pro.
Stated terms
- Stated value
- USD 450m (US$450 million)
- What the figure measures
- Issue size
- Client
- Not stated
- Counterparties
- CureVac N.V. (Issuer)